iRhythm up on Buy coverage at BofA on market expansion opportunities

[Wall Street New York City]
aluxum/E+ via Getty Images

iRhythm Technologies (NASDAQ:IRTC [https://seekingalpha.com/symbol/IRTC]) shares rise after BofA Securities initiated coverage with a Buy rating and a price objective of $200, banking on opportunities in the ambulatory cardiac monitoring market.

The research firm believes iRhythm is positioned as a disruptive force in ambulatory cardiac monitoring, with its Zio system, setting a new standard of care for diagnosing arrhythmias.

"The Zio system, a wireless patch-based sensor, is best in class for long term continuous monitoring of electrocardiogram data to diagnose arrhythmias. We see share gain potential in the mobile cardiac telemetry segment of the market, supported by Zio MCT launch in 2H26," analysts at BofA said.

Analysts added that the CEO, Quentin Blackford, has a history of executing on margin expansion and sees a clear path for profitability to improve.

The stock is up about 2% today.

MORE ON IRHYTHM TECHNOLOGIES

* iRhythm Technologies, Inc. (IRTC) Q2 2025 Earnings Call Transcript [https://seekingalpha.com/article/4807248-irhythm-technologies-inc-irtc-q2-2025-earnings-call-transcript]
* iRhythm: Promising Outlook - So Long As Past Mistakes Are Not Repeated [https://seekingalpha.com/article/4794478-irhythm-promising-outlook-so-long-as-past-mistakes-are-not-repeated]
* IRhythm raises 2025 revenue outlook to up to $730M as core and innovative channels accelerate [https://seekingalpha.com/news/4476208-irhythm-raises-2025-revenue-outlook-to-up-to-730m-as-core-and-innovative-channels-accelerate]
* iRhythm Technologies Q2 2025 Earnings Preview [https://seekingalpha.com/news/4474416-irhythm-technologies-q2-2025-earnings-preview]
* Seeking Alpha’s Quant Rating on iRhythm Technologies [https://seekingalpha.com/symbol/IRTC/ratings/quant-ratings]